A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
This study is investigating a new medicine called SHP611 for children diagnosed with Metachromatic Leukodystrophy (MLD). The main goal is to find out if SHP611, when injected directly into the fluid surrounding the brain and spinal cord, can help children keep their ability to walk and move around for a longer time. Researchers will also be observing how this medicine affects a child's movement and speech. Another important aim is to understand how well children tolerate the medicine and if there are any side effects. Children taking part in the study will receive SHP611 for around two years, with the possibility of continuing treatment for longer if the study shows it to be helpful.
En un coup d'œil
Résultats
Résultats de cette étude
Publié Juin 2024Les résultats de cette étude ont été publiés.
De quoi parle cette étude ?
This study is looking at a new approach to treating Metachromatic Leukodystrophy (MLD) in children. MLD is a rare genetic condition that affects the brain and nervous system, making it difficult for children to move, speak, and learn over time. Currently, there isn't a cure, so researchers are constantly working to find treatments that can help.
The medicine being tested in this study is called SHP611. It's given through an injection directly into the fluid that surrounds the brain and spinal cord, which is known as 'intrathecal' delivery. This method is used because it helps the medicine reach the areas where it's needed most to hopefully slow down the progression of the disease.
The main purpose of this study is to see if SHP611 can help children with MLD keep their ability to move around independently for a longer period. The researchers will also be carefully monitoring other important aspects of a child's health, such as their ability to speak and their overall movement. It's also very important to find out if SHP611 is safe and well-tolerated by children.
Points clés
- This study explores a new medicine (SHP611) for children with MLD.
- The medicine is given by injection into the spinal fluid.
- The main goal is to help children keep their ability to move for longer.
- Researchers will also check its effects on speech and safety.
- Participation lasts about two years, with possible extension.
Qui peut être éligible ?
To join this study, children must have a formal diagnosis of Metachromatic Leukodystrophy (MLD). This means tests would have shown specific changes in their blood (low ASA activity) and urine (high sulfatides).
Children need to be within a specific age range, generally between 6 months and 6 years old, depending on their specific MLD symptoms. They must also have certain levels of symptoms. For some, this means having difficulty walking due to MLD by 2 and a half years old. Others might be very young (6 to under 18 months), showing very few symptoms, but having the same MLD gene changes as an older child in their family. Another group might be between 12 and under 18 months old, showing early MLD symptoms, but having previously been able to walk steadily.
Finally, parents or legal guardians must be able to follow the study schedule and must give their written permission for their child to take part.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Does my child have a confirmed MLD diagnosis?
- Is my child between 6 months and 6 years old (age varies by specific MLD symptoms)?
- Does my child meet certain criteria for MLD symptom severity or progression?
- Can I commit to following the study's schedule of appointments and procedures?
- Am I able to give informed consent for my child to participate?
En quoi consiste la participation ?
If your child takes part in this study, they will receive the study medicine, SHP611, for about two years. There might be a chance to continue receiving the medicine for a longer time after this initial period. The medicine will be given by injection directly into the fluid around the brain and spinal cord.
Throughout the study, there will be regular visits to the clinic so that doctors can carefully monitor your child's health, track their movement and speech, and check for any changes or side effects. These assessments help the research team understand how the medicine is working and how your child is responding. You'll be given a detailed schedule of visits and what each visit will involve.
Risques et avantages potentiels
Locations (30)
- Los Angeles Biomedical Research Institute at Harbor-UCLACode postal vérifiéTorrance, United States
- Childrens Hospital ColoradoCode postal vérifiéAurora, États-Unis
- Rare Disease Research, LLCCode postal vérifiéAtlanta, États-Unis
- Ann & Robert H. Lurie Children's Hospital of ChicagoCode postal vérifiéChicago, États-Unis
- University of Iowa Stead Family Children's HospitalCode postal vérifiéIowa City, États-Unis
- Mayo Clinic - PPDSCode postal vérifiéRochester, États-Unis
- New York University Langone Medical CenterCode postal vérifiéNew York, États-Unis
- Cincinnati Children's Hospital Medical CenterCode postal vérifiéCincinnati, United States
- Children's Hospital of PhiladelphiaCode postal vérifiéPhiladelphie, États-Unis
- Children's Hospital of PittsburghCode postal vérifiéPittsburgh, United States
- Université de l'UtahCode postal vérifiéSalt Lake City, États-Unis
- Hospital Universitario Austral - PINVille uniquementCiudad Autónoma Buenos Aires, Argentina
Questions fréquentes
What is Metachromatic Leukodystrophy (MLD)?
MLD is a rare genetic disease that affects the brain and nervous system, leading to problems with movement, speech, and other abilities over time.
What is SHP611?
SHP611 is the experimental medicine being tested in this study. It's hoped it can help children with MLD.
How is SHP611 given?
It's given as an injection into the fluid that surrounds the brain and spinal cord, similar to a lumbar puncture.
How long will my child be in the study?
Children will receive the medicine for about two years, and there might be an option for longer treatment.
Is this medicine available to everyone?
No, SHP611 is an investigational medicine, which means it's still being studied and is not yet available outside of clinical trials.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.